Quest Diagnostics Inc (DGX) shareholders
Close on Nov 17, 2026Market cap $28.20BP/E 25.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9,308,815 | 8.40% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 8,274,567 | 7.53% | 13G (passive) | Mar 31, 2026 |
| Vanguard Portfolio Management | 6,096,629 | 5.54% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 5,563,421 | 5.00% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,275,411 | 8.43% | $1.97B | +103,119 | 0.03% |
| Vanguard Capital Management LLC | 7,233,394 | 6.57% | $1.53B | +87,722 | 0.03% |
| Vanguard Portfolio Management LLC | 6,131,045 | 5.57% | $1.30B | +49,645 | 0.06% |
| State Street Corp | 5,516,643 | 5.01% | $1.17B | +135,822 | 0.03% |
| Price T Rowe Associates Inc /Md/ | 5,444,986 | 4.95% | $1.15B | −853,001 | 0.12% |
| Boston Partners | 4,744,473 | 4.31% | $1.00B | +732,241 | 0.89% |
| JPMorgan Chase & Co | 3,520,438 | 3.20% | $748.59M | −326,018 | 0.04% |
| Geode Capital Management, LLC | 3,137,873 | 2.85% | $662.58M | +51,565 | 0.04% |
| Morgan Stanley | 2,460,497 | 2.24% | $521.50M | −19,223 | 0.03% |
| EdgePoint Investment Group Inc. | 2,247,568 | 2.04% | $476.37M | +3,699 | 3.60% |
| Dimensional Fund Advisors LP | 1,988,048 | 1.81% | $421.38M | +38,513 | 0.08% |
| Bank Of America Corp /De/ | 1,935,133 | 1.76% | $410.15M | +182,231 | 0.03% |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1,888,207 | 1.72% | $400.21M | +5,183 | 0.90% |
| Wells Fargo & Company/Mn | 1,751,220 | 1.59% | $371.17M | −11,549 | 0.06% |
| Davis Selected Advisers | 1,555,612 | 1.41% | $329.78M | −62,201 | 1.42% |
| Victory Capital Management Inc | 1,550,556 | 1.41% | $328.64M | −295,780 | 0.18% |
| Norges Bank | 1,406,620 | 1.28% | $298.13M | New | 0.03% |
| FMR LLC | 1,398,735 | 1.27% | $296.46M | +456,517 | 0.01% |
| Invesco Ltd. | 1,379,115 | 1.25% | $292.30M | −259,372 | 0.02% |
| Northern Trust Corp | 1,127,454 | 1.02% | $238.96M | +13,235 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,105 | 105M | 95.4% | 118 / 430 | 352 / 70 | 8M | 5M |
| Q1 2026 | 1,069 | 103M | 93.3% | 123 / 350 | 384 / 89 | 19M | 8M |
| Q4 2025 | 1,050 | 107M | 96.8% | 149 / 349 | 347 / 90 | 10M | 13M |
| Q3 2025 | 1,006 | 109M | 99.3% | 115 / 359 | 342 / 82 | 10M | 9M |
| Q2 2025 | 991 | 108M | 98.5% | 121 / 365 | 328 / 83 | 13M | 7M |
| Q1 2025 | 968 | 103M | 94.1% | 145 / 315 | 338 / 61 | 11M | 6M |
| Q4 2024 | 896 | 99M | 90.4% | 124 / 310 | 304 / 59 | 8M | 7M |
| Q3 2024 | 848 | 100M | 90.7% | 94 / 294 | 308 / 73 | 19M | 8M |
| Q2 2024 | 838 | 99M | 90.0% | 90 / 277 | 300 / 59 | 7M | 13M |
| Q1 2024 | 817 | 105M | 95.3% | 90 / 269 | 311 / 89 | 12M | 8M |
| Q4 2023 | 827 | 101M | 92.2% | 108 / 254 | 329 / 64 | 10M | 6M |
| Q3 2023 | 795 | 99M | 89.6% | 70 / 230 | 337 / 82 | 7M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
761 funds held DGX in Q2 2026, 49% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,514,526 | 3.19% | $744.90M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,868,317 | 2.61% | $607.94M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 2,398,588 | 2.18% | $508.38M | 0.23% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,519,109 | 1.38% | $321.98M | 0.04% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,407,676 | 1.28% | $274.36M | 0.03% | May 31, 2026 |
| Disciplined Value Mid Cap Fund | 1,222,712 | 1.11% | $259.15M | 1.12% | Jun 30, 2026 |
| JPMorgan Equity Income Fund | 1,153,090 | 1.05% | $244.40M | 0.56% | Jun 30, 2026 |
| T. Rowe Price Dividend Growth Fund, Inc. | 1,109,242 | 1.01% | $235.10M | 0.99% | Jun 30, 2026 |
| Disciplined Value Fund | 1,064,982 | 0.97% | $225.72M | 1.15% | Jun 30, 2026 |
| Victory Sycamore Established Value Fund | 1,055,000 | 0.96% | $223.61M | 1.45% | Jun 30, 2026 |
| Vanguard Value Index Fund | 1,052,676 | 0.96% | $223.11M | 0.09% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 915,193 | 0.83% | $213.25M | 0.22% | Jul 31, 2026 |
| JPMorgan Mid Cap Value Fund | 787,236 | 0.72% | $166.85M | 1.49% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 781,999 | 0.71% | $165.74M | 0.41% | Jun 30, 2026 |
| T. Rowe Price U.S. Large-Cap Core Fund, Inc. | 781,314 | 0.71% | $165.60M | 0.92% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| J. E. Davis | CEO and President, Director | 122,423 | 0.11% | Sep 3, 2026 |
| Michael J. Deppe | SVP, Corp. Controller & CAO | 35,916 | 0.03% | Nov 16, 2026 |
| Patrick Plewman | SVP for Diagnostic Services | 14,684 | 0.01% | Nov 12, 2026 |
| Subu Ramachandran | SVP, Regional Businesses | 2,832 | 0.00% | Nov 5, 2026 |
| Mark E. Delaney | SVP & Chief Commercial Officer | 12,975 | 0.01% | Nov 5, 2026 |
| Catherine T. Doherty | Executive Vice President | 76,501 | 0.07% | Nov 5, 2026 |
| Sam Samad | Executive Vice President & CFO | 33,568 | 0.03% | Oct 23, 2026 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 15,674 | 0.01% | Oct 23, 2026 |
| Michael E. Prevoznik | SVP & General Counsel | 66,014 | 0.06% | Aug 31, 2026 |
| Gary M. Pfeiffer | Director | 29,802 | 0.03% | Oct 28, 2026 |
| Robert B. Carter | Director | 3,874 | 0.00% | Oct 23, 2026 |
| Timothy L. Main | Director | 27,478 | 0.02% | Oct 23, 2026 |
| Wright Lassiter III | Director | 10,329 | 0.01% | Oct 23, 2026 |
| Vicky B. Gregg | Director | 18,449 | 0.02% | Oct 23, 2026 |
| Timothy C. Wentworth | Director | 1,358 | 0.00% | Oct 2, 2026 |
| Timothy M. Ring | Director | 31,140 | 0.03% | May 21, 2026 |
| Luis Diaz | Director | 5,196 | 0.00% | May 21, 2026 |
| Tracey Doi | Director | 7,748 | 0.01% | May 21, 2026 |
| Denise M. Morrison | Director | 11,929 | 0.01% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael J. Deppe SVP, Corp. Controller & CAO | Nov 13, 2026 | Sale(10b5-1 plan) | −5,515 | $260.17 | $1.43M | 35,203 |
| Michael J. Deppe SVP, Corp. Controller & CAO | Nov 13, 2026 | Option exercise | +5,515 | $103.57 | $571.19K | 40,718 |
| Michael J. Deppe SVP, Corp. Controller & CAO | Nov 13, 2026 | Sale(10b5-1 plan) | −6,261 | $260.17 | $1.63M | 35,203 |
| Michael J. Deppe SVP, Corp. Controller & CAO | Nov 13, 2026 | Option exercise | +6,261 | $95.80 | $599.77K | 41,464 |
| Patrick Plewman SVP for Diagnostic Services | Nov 9, 2026 | Sale(10b5-1 plan) | −650 | $257.34 | $167.27K | 14,684 |
| Patrick Plewman SVP for Diagnostic Services | Nov 9, 2026 | Sale(10b5-1 plan) | −6,793 | $257.34 | $1.75M | 15,334 |
| Patrick Plewman SVP for Diagnostic Services | Nov 9, 2026 | Option exercise | +6,793 | $127.81 | $868.18K | 22,127 |
| Patrick Plewman SVP for Diagnostic Services | Nov 9, 2026 | Sale(10b5-1 plan) | −4,274 | $257.34 | $1.10M | 15,334 |
| Patrick Plewman SVP for Diagnostic Services | Nov 9, 2026 | Option exercise | +4,274 | $127.72 | $545.90K | 19,608 |
| Subu Ramachandran SVP, Regional Businesses | Nov 3, 2026 | Award | +352 | – | – | 2,832 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −2,907 | $251.24 | $730.35K | 71,949 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −2,877 | $250.49 | $720.65K | 74,856 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −3,004 | $249.40 | $749.21K | 77,733 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −2,358 | $248.38 | $585.69K | 80,737 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −1,151 | $246.98 | $284.28K | 83,095 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −5,990 | $246.26 | $1.48M | 84,246 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Sale(10b5-1 plan) | −3,818 | $245.45 | $937.14K | 90,236 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Option exercise | +22,105 | $121.81 | $2.69M | 94,054 |
| Catherine T. Doherty Executive Vice President | Nov 3, 2026 | Award | +4,827 | – | – | 71,949 |
| Mark E. Delaney SVP & Chief Commercial Officer | Nov 3, 2026 | Award | +2,615 | – | – | 12,975 |
| Gary M. Pfeiffer Director | Oct 26, 2026 | Sale(10b5-1 plan) | −1,203 | $243.00 | $292.33K | 29,802 |
| Robert B. Carter Director | Oct 21, 2026 | Small purchase | +10 | $235.93 | $2.36K | 3,874 |
| Sam Samad Executive Vice President & CFO | Oct 21, 2026 | Award | +90 | $235.94 | $21.23K | 33,568 |
| Vicky B. Gregg Director | Oct 21, 2026 | Award | +63 | $235.94 | $14.86K | 18,449 |
| Karthik Kuppusamy SVP, Clinical Solutions | Oct 21, 2026 | Small purchase | +33 | $235.94 | $7.79K | 13,619 |
| Wright Lassiter III Director | Oct 21, 2026 | Small purchase | +6 | $235.96 | $1.42K | 10,329 |
| Patrick Plewman SVP for Diagnostic Services | Oct 21, 2026 | Small purchase | +41 | $235.94 | $9.67K | 15,334 |
| Timothy L. Main Director | Oct 21, 2026 | Small purchase | +18 | $235.94 | $4.25K | 22,478 |
| Mark E. Delaney SVP & Chief Commercial Officer | Oct 21, 2026 | Small purchase | +25 | $235.94 | $5.90K | 10,360 |
| J. E. Davis CEO and President, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −10,000 | $242.72 | $2.43M | 122,423 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Option exercise | +22,677 | $112.17 | $2.54M | 60,234 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −16,010 | $242.88 | $3.89M | 44,224 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −6,237 | $243.63 | $1.52M | 37,987 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Sale(10b5-1 plan) | −430 | $244.51 | $105.14K | 37,557 |
| Michael E. Prevoznik SVP & General Counsel | Aug 28, 2026 | Gift | −1,000 | – | – | 36,557 |
| Mark E. Delaney SVP & Chief Commercial Officer | Jul 28, 2026 | Sale(10b5-1 plan) | −1,600 | $235.18 | $376.29K | 10,335 |
| Vicky B. Gregg Director | Jul 22, 2026 | Award | +72 | $206.81 | $14.89K | 18,386 |
| Robert B. Carter Director | Jul 22, 2026 | Small purchase | +11 | $206.80 | $2.27K | 3,864 |
| Patrick Plewman SVP for Diagnostic Services | Jul 22, 2026 | Small purchase | +46 | $206.81 | $9.51K | 15,293 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jul 22, 2026 | Small purchase | +37 | $206.81 | $7.65K | 13,557 |
| Wright Lassiter III Director | Jul 22, 2026 | Small purchase | +6 | $206.81 | $1.24K | 10,323 |
| Mark E. Delaney SVP & Chief Commercial Officer | Jul 22, 2026 | Small purchase | +34 | $206.81 | $7.03K | 11,935 |
| Sam Samad Executive Vice President & CFO | Jul 22, 2026 | Award | +102 | $206.81 | $21.09K | 33,478 |
| Timothy L. Main Director | Jul 22, 2026 | Small purchase | +21 | $206.81 | $4.34K | 22,460 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Sale(10b5-1 plan) | −8,147 | $200.00 | $1.63M | 13,510 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Option exercise | +3,320 | $127.73 | $424.06K | 16,830 |
| Karthik Kuppusamy SVP, Clinical Solutions | Jun 4, 2026 | Option exercise | +4,827 | $121.81 | $587.98K | 21,657 |
| J. E. Davis CEO and President, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −10,000 | $194.14 | $1.94M | 132,423 |
| Vicky B. Gregg Director | May 20, 2026 | Award | +1,142 | – | – | 18,314 |
| Timothy L. Main Director | May 20, 2026 | Award | +1,142 | – | – | 27,439 |
| Tracey Doi Director | May 20, 2026 | Award | +1,142 | – | – | 7,748 |
| Gary M. Pfeiffer Director | May 20, 2026 | Award | +1,142 | – | – | 31,005 |
| Robert B. Carter Director | May 20, 2026 | Award | +1,142 | – | – | 3,853 |
| Timothy C. Wentworth Director | May 20, 2026 | Award | +1,142 | – | – | 1,358 |
| Wright Lassiter III Director | May 20, 2026 | Award | +1,142 | – | – | 10,317 |
| Timothy M. Ring Director | May 20, 2026 | Award | +1,142 | – | – | 31,140 |
| Luis Diaz Director | May 20, 2026 | Award | +1,142 | – | – | 5,196 |
| Denise M. Morrison Director | May 20, 2026 | Award | +1,142 | – | – | 11,929 |
| Patrick Plewman SVP for Diagnostic Services | Apr 20, 2026 | Small purchase | +49 | $194.70 | $9.54K | 15,247 |
| Robert B. Carter Director | Apr 20, 2026 | Small purchase | +7 | $194.70 | $1.36K | 2,711 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Quest Diagnostics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,712 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Patrick Plewman Officer | Nov 9, 2026 | 11,717 | $3.02M | Nov 9, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Nov 3, 2026 | 22,105 | $5.58M | Nov 3, 2026 | Stock Option Exercise |
| Gary M. Pfeiffer Director | Oct 26, 2026 | 1,203 | $292.33K | Oct 26, 2026 | Restricted Stock Vesting |
| J. E. Davis Officer, Director | Sep 1, 2026 | 10,000 | $2.43M | Sep 1, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Aug 28, 2026 | 22,677 | $5.51M | Aug 28, 2026 | Stock Option Exercise |
| Mark E. Delaney Officer | Jul 28, 2026 | 1,600 | $376.29K | Jul 28, 2026 | Restricted Stock Vesting |
| Karthik Kuppusamy Officer | Jun 4, 2026 | 8,147 | $1.63M | Jun 4, 2026 | Stock Option Exercise |
| J. E. Davis Officer, Director | Jun 1, 2026 | 10,000 | $1.94M | Jun 1, 2026 | Restricted Stock Vesting |
| Patrick Plewman Officer | Mar 5, 2026 | 2,855 | $588.73K | Mar 5, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Mar 5, 2026 | 5,558 | $1.15M | Mar 5, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Mar 5, 2026 | 3,878 | $799.68K | Mar 5, 2026 | Restricted Stock Vesting |
| Michael E. Prevoznik Officer | Mar 3, 2026 | 526 | $109.27K | Mar 3, 2026 | Restricted Stock Vesting |
| Catherine T. Doherty Officer | Mar 3, 2026 | 632 | $131.29K | Mar 3, 2026 | Restricted Stock Vesting |
| Patrick Plewman Officer | Mar 3, 2026 | 410 | $85.17K | Mar 3, 2026 | Restricted Stock Vesting |
| J. E. Davis Officer, Director | Mar 2, 2026 | 10,000 | $2.13M | Mar 2, 2026 | Restricted Stock Vesting |
Congress trades
18 trades in Quest Diagnostics reported by 8 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Julie Johnson TX32 · joint account | Sold | Nov 3, 2025 | $1K–15K | Dec 11, 2025 |
| Julie Johnson TX32 · joint account | Bought | Oct 30, 2025 | $1K–15K | Aug 5, 2026 279 days late |
| Julie Johnson TX32 · joint account | Sold | Oct 30, 2025 | $1K–15K | Aug 5, 2026 279 days late |
| Julia Letlow LA05 | Sold | Jul 24, 2025 | $1K–15K | Jan 13, 2026 173 days late |
| Julia Letlow LA05 | Bought | Apr 28, 2025 | $1K–15K | Jan 13, 2026 260 days late |
| Carol Devine Miller WV01 | Sold | Mar 10, 2025 | $15K–50K | Aug 13, 2026 521 days late |
| Carol Devine Miller WV01 | Sold | Mar 10, 2025 | $1K–15K | Apr 11, 2025 |
| Earl Blumenauer OR03 · spouse | Sold | Apr 4, 2024 | $1K–15K | May 4, 2024 |
| Carol Devine Miller WV01 | Bought | Nov 14, 2022 | $1K–15K | Dec 13, 2022 |
| Kathy Manning NC06 · joint account | Sold | Aug 3, 2022 | $1K–15K | Sep 14, 2022 |
| Kathy Manning NC06 · joint account | Bought | Jul 20, 2022 | $1K–15K | Aug 10, 2022 |
| Carol Devine Miller WV01 · spouse | Bought | Jul 28, 2021 | $15K–50K | Sep 2, 2022 401 days late |
| K. Michael Conaway TX11 · spouse | Sold | Sep 12, 2016 | $1K–15K | Oct 12, 2016 |
| Lois Frankel FL22 | Sold | Jun 20, 2016 | $1K–15K | Aug 16, 2016 57 days late |
| Lois Frankel FL22 | Sold | May 27, 2015 | $1K–15K | Jun 19, 2015 |
| Richard L. Hanna NY22 · joint account | Sold | Oct 15, 2014 | $1K–15K | Nov 11, 2014 |
| Richard L. Hanna NY22 | Sold | Dec 30, 2013 | $1K–15K | Jan 15, 2014 |
| Richard L. Hanna NY22 | Sold | Dec 27, 2013 | $100K–250K | Jan 15, 2014 |
See a number that looks wrong?